miR-1182 inhibits growth and mediates the chemosensitivity of bladder cancer by targeting hTERT

Biochemical and Biophysical Research Communications
Jun ZhouJianming Song

Abstract

microRNAs (miRNAs) have been demonstrated to contribute to tumor progression and metastasis and proposed to be key regulators of diverse biological processes. In this study, we report that miR-1182 is deregulated in bladder cancer tissues and cell lines. To characterize the role of miR-1182 in bladder cancer cells, we performed functional assays. The overexpression of miR-1182 significantly inhibits bladder cancer cell proliferation, colony formation, and invasion. Moreover, its up-regulation induced cell cycle arrest and apoptosis and mediated chemosensitivity to cisplatin in bladder cancer. Furthermore, a luciferase reporter assay and a rescue experiment indicated that miR-1182 directly targets hTERT by binding its 3'UTR. In conclusion, these results demonstrate that miR-1182 acts as a tumor suppressor and may be a potential biomarker for bladder cancer diagnosis and treatment.

References

Jun 15, 2006·Nature Reviews. Drug Discovery·Jerry W Shay, Woodring E Wright
Jan 16, 2007·The Journal of Urology·Harry W HerrDean F Bajorin
Dec 23, 2009·The International Journal of Biochemistry & Cell Biology·William C S Cho
Jun 16, 2010·International Journal of Cancer. Journal International Du Cancer·Li HuangTianxin Lin
Feb 8, 2011·European Urology·James W F CattoTapio Visakorpi
Dec 31, 2011·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Yafei ZhangDianchun Fang
Mar 20, 2012·The American Journal of Pathology·Patricia Puerta-GilMarta Sánchez-Carbayo
Oct 3, 2012·International Journal of Oncology·Alessandro AllegraCaterina Musolino
Oct 9, 2012·Seminars in Oncology·Vinod H NargundM N Kabir
Feb 8, 2013·BJU International·Eran RosenbergOfer Nativ
Jul 24, 2013·Trends in Genetics : TIG·Bruno Bernardes de Jesus, Maria A Blasco
Jan 31, 2014·Nature·UNKNOWN Cancer Genome Atlas Research Network
Oct 8, 2014·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Ye LeiMinfeng Chen
Dec 30, 2014·Biochimica Et Biophysica Acta·Hui DengJingde Zhu
Jan 1, 2015·Journal of Experimental & Clinical Cancer Research : CR·Gan YuBin Lang
Jan 9, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Yongchao JinXiaofei Wen

❮ Previous
Next ❯

Citations

Apr 16, 2016·Arteriosclerosis, Thrombosis, and Vascular Biology·Matthew J DurandAndreas M Beyer
Jun 22, 2016·Investigative and Clinical Urology·Hideki EnokidaMasayuki Nakagawa
Oct 11, 2019·Nucleic Acids Research·Bastian FrommKevin J Peterson
Jun 13, 2019·Cell Communication and Signaling : CCS·Meng-Meng JieXin-Zhe Li
Apr 5, 2018·International Journal of Molecular Sciences·Ammad Ahmad FarooqiBaojun Xu
Nov 2, 2019·Journal of Experimental & Clinical Cancer Research : CR·Zhi-Hong ZongYang Zhao
Mar 13, 2018·Journal of Biomedical Science·Ricardo LeãoPedro Castelo-Branco
Oct 24, 2020·Current Genomics·Daniel Humberto PozzaVamsidhar Velcheti
Jul 17, 2020·International Journal of Biological Macromolecules·Jiequan WangXinhua Liu
Apr 4, 2021·Cancers·Fatma Dogan, Nicholas R Forsyth
Sep 6, 2020·Life Sciences·Aysan SalamatiBahman Yousefi
Aug 10, 2020·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Min ZhaoChaonan Ma

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis